Open AccessCompetitive ELISA for detection of native ras gene‐related products in sera of cancer patients
Author(s) -
Epelbaum R.,
Bartal A. H.,
Rivkin M.,
Tugendhaft N.,
Shalitin C.
Publication year - 1989
Publication title -
journal of clinical laboratory analysis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.536
H-Index - 50
eISSN - 1098-2825
pISSN - 0887-8013
DOI - 10.1002/jcla.1860030404
Subject(s) - antibody , monoclonal antibody , cancer , disease , immunology , gene , medicine , microbiology and biotechnology , biology , genetics
A solid phase, enzyme‐linked immunosorbent assay (ELISA) competition kit was developed to detect circulating native ras gene‐related products in sera of 151 healthy volunteers and cancer patients. This assay uses monoclonal antibody (mAb) BST‐6A generated against a yeast‐derived, native ras‐related polypeptide Yp20. Only 2% (1 of 58) of normal control sera showed strong competition, as compared to 15% (5 of 34) of patients with early stage or no evidence of disease, and 44% (26 of 59) of patients with advanced disease. These differences were statistically significant (X 2 , P < 0.05–0.001). Eleven sera samples of cancer patients found to be strong competitors in the ELISA competition kit were tested for the presence of anti‐ras antibodies by ELISA. None showed higher ELISA values as compared with pooled normal human serum and control sera. It is thus suggested that our procedure detected circulating ras‐related oncoproteins in sera of cancer patients mainly with advanced disease.